

## Oral communications: Drug Design Theme (Wednesday).

### Ruthenium Complexes for the Treatment of Protozoan Diseases

Afonso P. Basto<sup>a</sup>, Joachim Müller<sup>a</sup>, Riccardo Rubbiani<sup>b</sup>, Federico Giannini<sup>c</sup>, David Stibal<sup>d</sup>, Georg Süss-Fink<sup>d</sup>, Vreni Balmer<sup>a</sup>, Andrew Hemphill<sup>a</sup>, Gilles Gasser<sup>e</sup>, Julien Furrer<sup>c</sup>

*a* Institute of Parasitology, Vetsuisse Faculty, University of Bern, Länggassstrasse 122, CH-3012 Berne, Switzerland.

*b* Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.

*c* Department for Chemistry and Biochemistry, Freiestrasse 3 CH-3012 Bern, Switzerland.

*d* Institut de Chimie, Université de Neuchâtel, Avenue de Bellevaux 51, CH-2000 Neuchâtel, Switzerland.

*e* Chimie ParisTech, PSL Research University, Laboratory for Inorganic Chemical Biology, F-14 75005 Paris, France.

E-mail: [julien.furrer@dcb.unibe.ch](mailto:julien.furrer@dcb.unibe.ch)

Recently, some of us have shown that dinuclear thiolato-bridged arene ruthenium complexes of the type  $[(\eta^6\text{-}p\text{-cymene})_2\text{Ru}_2(\mu_2\text{-SR})_3]^+$  were among the most cytotoxic ruthenium complexes reported so far, with nanomolar  $\text{IC}_{50}$  values against both A2780 human ovarian cancer cells and their cisplatin-resistant mutant variant A2780cisR.[1] Interestingly, *in vivo* studies of *diruthenium-1*,  $[(\eta^6\text{-}p\text{-cymene})_2\text{Ru}_2(\mu_2\text{-SC}_6\text{H}_4\text{-}p\text{-Bu}^t)_3]^+$ , demonstrated a significant increase in survival of the treated mouse group.[2-3]

Motivated by the impressive results obtained in cancer therapy, we decided to test some of those compounds against *Neospora caninum* and *Toxoplasma gondii*. Two complexes, namely  $[(\eta^6\text{-}p\text{-cymene})_2\text{Ru}_2(\mu_2\text{-SC}_6\text{H}_4\text{-}p\text{-CH}_3)_3]^+$  and *diruthenium-1*, displayed  $\text{IC}_{50}$  values on *T. gondii* of 34 and 62 nM, respectively, with a high selectivity on *T. gondii* over human foreskin fibroblasts (HFF) as expressed by a selectivity index of around 20'000. Transmission electron microscopy (TEM) showed that treatment with these compounds has a dramatic impact on the parasite mitochondrion [4]. Moreover, upon treatment of human ovarian carcinoma A2780 cells with these drugs, between 71 and 97% of the ruthenium was found to accumulate in the mitochondria. This strongly suggests that these compounds are targeting the mitochondria in both parasites and cancer cells. *Giardia lamblia* that is devoid of functional mitochondria is not affected by treatments with these complexes up to a concentration of 5  $\mu\text{M}$ , thus further supporting this statement.

- [1] J. Furrer, G. Süss-Fink, *Coord. Chem. Rev.* **2016**, 309, 36-50.
- [2] P. Tomšik, D. Muthná, M. Řezáčová, S. Mičuda, J. Čmielová, M. Hroch, R. Endlicher, Z. Červinková, E. Rudolf, S. Hann, D. Stibal, B. Therrien, G. Süss-Fink, J. *Organomet. Chem.* **2015**, 782, 42-51.
- [3] A. Koceva-Chyla, K. Matczak, P. Hikiş, K. Durka, K. Kochel, G. Süss-Fink, J. Furrer, K. Kowalski, *ChemMedChem*, **2016**, 11, 2171-2187.
- [4] A. P. Basto, J. Müller, R. Rubbiani, D. Stibal, F. Giannini, G. Süss-Fink, V. Balmer, A. Hemphill, G. Gasser, J. Furrer, *Antimicrob. Agents Chemother.* **2017**, 61, e01031-17.

Targeted chemotherapy towards diseases caused by endoparasites. COST Action CM1307  
25<sup>th</sup>-27<sup>th</sup> of October, 2017, Lausanne, Switzerland